Post-earnings recap
Reported
Thu, Aug 12, 2010
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a narrower-than-expected loss per share, leading to a positive stock reaction with a 0.96% increase. The company did not disclose revenue figures or future guidance, which leaves some uncertainty for investors. The positive EPS surprise suggests that the company is managing its costs effectively, which may instill some confidence among shareholders.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +80.00% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, indicating positive momentum. However, they did not provide specific guidance for future quarters.
The company is pleased with the progress made this quarter.
Management highlighted ongoing developments in their pipeline.